HRP20210861T1 - Topiva kapsula estradiola za vaginalnu inserciju - Google Patents
Topiva kapsula estradiola za vaginalnu inserciju Download PDFInfo
- Publication number
- HRP20210861T1 HRP20210861T1 HRP20210861TT HRP20210861T HRP20210861T1 HR P20210861 T1 HRP20210861 T1 HR P20210861T1 HR P20210861T T HRP20210861T T HR P20210861TT HR P20210861 T HRP20210861 T HR P20210861T HR P20210861 T1 HRP20210861 T1 HR P20210861T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- formulation according
- fatty acid
- estradiol
- micrograms
- Prior art date
Links
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims 6
- 229960005309 estradiol Drugs 0.000 title claims 6
- 229930182833 estradiol Natural products 0.000 title claims 6
- 239000002775 capsule Substances 0.000 title 1
- 230000037431 insertion Effects 0.000 title 1
- 238000003780 insertion Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- -1 caprylic fatty acid Chemical class 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims 2
- 208000004483 Dyspareunia Diseases 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 239000007901 soft capsule Substances 0.000 claims 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 206010030247 Oestrogen deficiency Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 239000000227 bioadhesive Substances 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 229940119517 peg-6 stearate Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims 1
- 150000005691 triesters Chemical class 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (15)
1. Kapsulirana farmaceutska formulacija za intravaginalnu primjenu, koja sadrži:
estradiol otopljen u otapajućem sredstvu koje je C6-C12 masna kiselina mono-, di- ili triester glicerola;
pri čemu formulacija sadrži od 1 mikrograma do 25 mikrograma estradiola; i pri čemu formulacija ne uključuje hidrofilno bioadhezivno sredstvo koje stvara gel.
2. Formulacija prema zahtjevu 1, naznačena time, da formulacija sadrži od 1 mikrograma do 10 mikrograma estradiola.
3. Formulacija prema zahtjevu 2, naznačena time što formulacija sadrži 5 mikrograma estradiola.
4. Formulacija prema zahtjevu 2, naznačena time, da formulacija sadrži 2.5 mikrograma estradiola.
5. Formulacija prema bilo kojem od zahtjeva 1-4, naznačena time što je formulacija inkapsulirana u meku kapsulu.
6. Formulacija prema zahtjevu 5, naznačena time, da je meka kapsula meka želatinska kapsula.
7. Formulacija prema bilo kojem od zahtjeva 1-6, naznačena time, da sredstvo za otapanje sadrži kaproinsku masnu kiselinu, kaprilnu masnu kiselinu, kaprinsku masnu kiselinu, ester kapronske masne kiseline, ester kaprilne masne kiseline, ester kaprinske masne kiseline , ili kombinaciju dviju ili više njih.
8. Formulacija prema bilo kojem od zahtjeva 1-7, naznačena time, da sredstvo za otapanje sadrži monoglicerid, diglicerid ili ester triglicerida najmanje jedne C6-C12 masne kiseline.
9. Formulacija prema bilo kojem od zahtjeva 1-8, naznačena time što sredstvo za otapanje sadrži kapril / kaprinski triglicerid.
10. Formulacija prema bilo kojem od zahtjeva 1-9, naznačena time, da je sredstvo za otapanje pretežno C6-C12 trigliceridni ester.
11. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time, da formulacija nadalje sadrži neionsko površinski aktivno sredstvo koje sadrži PEG-6 stearat i etilen glikol palmitostearat.
12. Formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time, da se koristi u liječenju vulvovaginalne atrofije intravaginalnom isporukom.
13. Formulacija prema bilo kojem od zahtjeva 1 do 11, naznačena time, da se upotrebljava u liječenju urinarnog stanja s nedostatkom estrogena putem intravaginalne isporuke.
14. Formulacija prema bilo kojem od zahtjeva 1 do 11, naznačena time, da se koristi u liječenju simptoma povezanih s vulvovaginalnom atrofijom, odabranim između suhoće, svrbeža, bolnosti, iritacije, krvarenja i dispareunije.
15. Formulacija za uporabu prema zahtjevu 14, naznačena time, da se koristi u liječenju dispareunije.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661302P | 2012-06-18 | 2012-06-18 | |
US201261662265P | 2012-06-20 | 2012-06-20 | |
US13/684,002 US8633178B2 (en) | 2011-11-23 | 2012-11-21 | Natural combination hormone replacement formulations and therapies |
US201261745313P | 2012-12-21 | 2012-12-21 | |
PCT/US2013/023309 WO2013112947A1 (en) | 2012-01-26 | 2013-01-25 | Transdermal hormone replacement therapies |
US13/843,428 US9301920B2 (en) | 2012-06-18 | 2013-03-15 | Natural combination hormone replacement formulations and therapies |
EP13807188.1A EP2861073B1 (en) | 2012-06-18 | 2013-06-18 | Soluble estradiol capsule for vaginal insertion |
PCT/US2013/046443 WO2013192249A1 (en) | 2012-06-18 | 2013-06-18 | Soluble estradiol capsule for vaginal insertion |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210861T1 true HRP20210861T1 (hr) | 2021-09-17 |
Family
ID=49769313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210861TT HRP20210861T1 (hr) | 2012-06-18 | 2021-05-31 | Topiva kapsula estradiola za vaginalnu inserciju |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP3909586A1 (hr) |
JP (3) | JP6397402B2 (hr) |
AU (3) | AU2013277234B2 (hr) |
BR (1) | BR112014031914B1 (hr) |
CA (1) | CA2876968C (hr) |
ES (1) | ES2869250T3 (hr) |
HR (1) | HRP20210861T1 (hr) |
HU (1) | HUE055275T2 (hr) |
IL (1) | IL236359B (hr) |
MX (1) | MX358435B (hr) |
PL (1) | PL2861073T3 (hr) |
RU (2) | RU2020140867A (hr) |
WO (1) | WO2013192249A1 (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
JP2018538290A (ja) * | 2015-12-07 | 2018-12-27 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 膣挿入エストラジオール医薬組成物および方法 |
WO2017105512A1 (en) * | 2015-12-18 | 2017-06-22 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
EP4051203A4 (en) * | 2019-10-31 | 2023-10-25 | R.P. Scherer Technologies, LLC | SUPPOSITORY CAPSULE |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US694192A (en) * | 1901-04-20 | 1902-02-25 | William C Rastetter | Vehicle-wheel. |
IT1090703B (it) * | 1976-12-03 | 1985-06-26 | Scherer Ltd R P | Perfezionamento nelle composizioni utili quali veicolo per farmaci |
US4384096A (en) * | 1979-08-27 | 1983-05-17 | The Dow Chemical Company | Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems |
FR2668945B1 (fr) * | 1990-11-12 | 1993-02-19 | Theramex | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2728464B1 (fr) * | 1994-12-22 | 1997-04-30 | Innothera Lab Sa | Forme galenique unitaire, son procede d'obtention et ses utilisations |
FR2739558B1 (fr) | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale |
GB9608719D0 (en) * | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
US6018033A (en) | 1997-05-13 | 2000-01-25 | Purdue Research Foundation | Hydrophilic, hydrophobic, and thermoreversible saccharide gels and forms, and methods for producing same |
NZ330726A (en) * | 1998-06-18 | 2000-10-27 | Dec Res | Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US20030083286A1 (en) * | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20060134188A1 (en) * | 2004-12-20 | 2006-06-22 | Hans-Peter Podhaisky | Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient |
US20070036843A1 (en) * | 2005-01-28 | 2007-02-15 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
WO2007076144A2 (en) * | 2005-12-27 | 2007-07-05 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
US20070264349A1 (en) * | 2006-03-07 | 2007-11-15 | Novavax, Inc. | Nano-structured compositions and methods of making and using the same |
FR2900052B1 (fr) * | 2006-04-19 | 2011-02-18 | Galderma Sa | Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine |
US20070287789A1 (en) * | 2006-06-07 | 2007-12-13 | Stephen Ray Jones | Bleed-resistant colored microparticles |
CN101474167A (zh) * | 2009-01-23 | 2009-07-08 | 西安德天药业股份有限公司 | 雌二醇阴道用胶囊的制备方法 |
US9301920B2 (en) * | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
RS62297B1 (sr) * | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
-
2013
- 2013-06-18 ES ES13807188T patent/ES2869250T3/es active Active
- 2013-06-18 JP JP2015517489A patent/JP6397402B2/ja active Active
- 2013-06-18 PL PL13807188T patent/PL2861073T3/pl unknown
- 2013-06-18 HU HUE13807188A patent/HUE055275T2/hu unknown
- 2013-06-18 RU RU2020140867A patent/RU2020140867A/ru unknown
- 2013-06-18 EP EP21167943.6A patent/EP3909586A1/en not_active Withdrawn
- 2013-06-18 CA CA2876968A patent/CA2876968C/en active Active
- 2013-06-18 AU AU2013277234A patent/AU2013277234B2/en active Active
- 2013-06-18 EP EP13807188.1A patent/EP2861073B1/en not_active Revoked
- 2013-06-18 WO PCT/US2013/046443 patent/WO2013192249A1/en active Application Filing
- 2013-06-18 BR BR112014031914-6A patent/BR112014031914B1/pt active IP Right Grant
- 2013-06-18 RU RU2015100531A patent/RU2740059C2/ru active
- 2013-06-18 MX MX2014015899A patent/MX358435B/es active IP Right Grant
-
2014
- 2014-12-18 IL IL236359A patent/IL236359B/en active IP Right Grant
-
2017
- 2017-07-27 AU AU2017208300A patent/AU2017208300A1/en not_active Abandoned
-
2018
- 2018-08-31 JP JP2018162966A patent/JP6682127B2/ja active Active
-
2019
- 2019-06-28 AU AU2019204653A patent/AU2019204653B2/en not_active Ceased
-
2020
- 2020-02-26 JP JP2020030544A patent/JP2020100642A/ja active Pending
-
2021
- 2021-05-31 HR HRP20210861TT patent/HRP20210861T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013277234A1 (en) | 2015-01-22 |
MX2014015899A (es) | 2015-03-03 |
EP3909586A1 (en) | 2021-11-17 |
EP2861073A1 (en) | 2015-04-22 |
JP2018199711A (ja) | 2018-12-20 |
JP6682127B2 (ja) | 2020-04-15 |
CA2876968A1 (en) | 2013-12-27 |
HUE055275T2 (hu) | 2021-11-29 |
RU2740059C2 (ru) | 2020-12-31 |
CA2876968C (en) | 2022-09-13 |
IL236359A0 (en) | 2015-02-26 |
MX358435B (es) | 2018-08-03 |
EP2861073A4 (en) | 2015-12-23 |
AU2013277234B2 (en) | 2017-04-27 |
AU2019204653A1 (en) | 2019-07-18 |
ES2869250T3 (es) | 2021-10-25 |
JP6397402B2 (ja) | 2018-09-26 |
JP2015519405A (ja) | 2015-07-09 |
EP2861073B1 (en) | 2021-04-14 |
BR112014031914B1 (pt) | 2021-12-14 |
AU2019204653B2 (en) | 2021-07-08 |
RU2020140867A (ru) | 2021-06-10 |
BR112014031914A2 (pt) | 2017-06-27 |
PL2861073T3 (pl) | 2021-09-27 |
AU2017208300A1 (en) | 2017-08-17 |
JP2020100642A (ja) | 2020-07-02 |
WO2013192249A1 (en) | 2013-12-27 |
RU2015100531A (ru) | 2016-08-10 |
IL236359B (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210861T1 (hr) | Topiva kapsula estradiola za vaginalnu inserciju | |
US11065197B2 (en) | Soluble estradiol capsule for vaginal insertion | |
JP2015519405A5 (hr) | ||
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
HRP20211377T1 (hr) | Prirodne kombinirane hormonske supstitucijske formulacije i terapije | |
BR112012010083B8 (pt) | Composição farmacêutica tópica de liberação sustentada e uso relacionado | |
HRP20210865T1 (hr) | Ulje-u-vodi nanoemulzijski pripravak klobetazola | |
KR102163369B1 (ko) | 질 삽입용 가용성 에스트라디올 캡슐 | |
AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
CA2661099A1 (en) | Pharmaceutical compositions comprising cefquinome | |
AR127914A2 (es) | Composiciones farmacéuticas de estradiol insertadas en la vagina y procedimientos | |
EA037435B1 (ru) | Фармацевтическая композиция, содержащая бензидамин | |
RU2016118396A (ru) | Фармацевтические составы и способы на основе эстрадиола для интравагинального введения | |
Ruban et al. | The development of vaginal gel |